The IGFBP-2 is considered a key factor in prostate cancer progression (Degraff et al, 2009) with levels of IGFBP-2 being elevated in patients with CaP, both in serum where levels correlate with those of PSA (Kanety et al, 1993) and in the tumours (Bubendorf et al, 1999). Here, IGFBP2 is linked to prostate cancer.